Ligand Pharmaceuticals Inc. Share Price OTC Bulletin Board
Equities
US53220K1815
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 138M 11.49B | Sales 2025 * | 157M 13.12B | Capitalization | 1.51B 126B |
---|---|---|---|---|---|
Net income 2024 * | 92M 7.67B | Net income 2025 * | 50M 4.17B | EV / Sales 2024 * | 11 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.61 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
26.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.65% |
Latest transcript on Ligand Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 01/07/01 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 01/22/01 |
President | 49 | 06/15/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 01/03/01 |
John LaMattina
BRD | Director/Board Member | 74 | 01/11/01 |
Stephen Sabba
BRD | Director/Board Member | 64 | 04/08/04 |
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |